Asset / Drug

Other

Drug and asset intelligence for Other with 15 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 0
Catalysts: 15
Stage: Development stage unavailable

Sponsor company

Lilly →

Recent signals

No signals indexed for this entity yet.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(15)

Topline Data

— Other

Monitor vaccination rates, government health initiatives, and any new HPV vaccine approvals or partnerships in the region.

June 21, 2026 · N/A

Topline Data

— Other

Monitor clinical trials assessing the efficacy of maraviroc, navarixin, and anakinra in TNBC settings.

June 21, 2026 · N/A

Topline Data

— Other

Monitor developments in circKPNA2-targeted therapies and clinical trials assessing its role in CRC treatment.

June 21, 2026 · N/A

Topline Data

— Other

Monitor ongoing research into probiotics in cancer therapy and clinical trials targeting ferroptosis in ESCC.

June 21, 2026 · N/A

Topline Data

— Other

Monitor advancements in delivery device technologies and formulation strategies that improve patient outcomes in biologics.

June 21, 2026 · N/A

Topline Data

— Other

Monitor adoption rates and reimbursement decisions for FF/UMEC/VI in Saudi Arabia.

June 21, 2026 · N/A

Topline Data

— Other

Monitor publications and emerging research themes related to tumor microenvironment and resistance mechanisms in CAR-T therapies.

June 21, 2026 · N/A

Topline Data

— Other

Monitor further studies on excipient interactions and their impact on mAb formulation stability and viscosity.

June 21, 2026 · N/A

Topline Data

— Other

Monitor ongoing research and clinical trials targeting FCGR2B in cancer immunotherapy, as well as developments in related metabolic modulation strategies.

June 20, 2026 · N/A

Topline Data

— Other

Monitor research on metabolic inhibitors and their effects on GSH and H2S in various cancer types.

June 20, 2026 · N/A

Topline Data

— Other

Monitor updates from the FDA regarding the resolution of the supply disruption and any impact on market competitors.

June 20, 2026 · N/A

Topline Data

— Other

Monitor further studies validating these genetic associations and any emerging therapies targeting these pathways.

June 20, 2026 · N/A

Topline Data

Lilly — Other

Monitor patient uptake and feedback on Zepbound® following the campaign, as well as any competitive responses from other OSA treatments.

June 15, 2026 · N/A

Topline Data

— Other

Monitor advancements in ncRNA-targeted therapies and their clinical trials in PDAC.

June 15, 2026 · N/A

Topline Data

— Other

Monitor further studies on the clinical application of LIPUS-microbubble techniques and potential partnerships for technology development.

June 10, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Biologics · Drug Delivery →

Endocrinology · Polycystic Ovary Syndrome →

Immunology · Monoclonal Antibodies →

Infectious Disease · Fungal Infections →

Oncology · Breast Cancer →

Oncology · CAR-T →

Oncology · Colorectal Cancer →

Oncology · Esophageal Squamous Cell Carcinoma →

Oncology · HPV-related Cancers →

Oncology · Immunotherapy →

Oncology · Medical Devices →

Oncology · Metabolic Reprogramming →

Oncology · Pancreatic Cancer →

Pulmonology · Obstructive Sleep Apnea →

Respiratory · Asthma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.